Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Komipharm International Co., Ltd. (041960.KQ)
Siheung‑Si, KR
Komipharm International Co., Ltd. is a South Korean biopharmaceutical firm specializing in the research, development, and production of veterinary pharmaceuticals and animal vaccines. Their extensive portfolio features vaccines designed for livestock like swine, cattle, and poultry, as well as companion animals such as canines. Complementing these, they offer antibiotics, disinfectants, and bio-fertilizers, in addition to providing clinical laboratory services. The company is also expanding its focus to human health, with ongoing development of anticancer drugs and pain management agents.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.97% | -9.56% | -18.48% | -7.54% | +28.69% | +4.25% | +45.10% | +10.63% | -16.11% | -73.60% | +678.21% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-10.7% Q1'26: -17.2% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%-153.6% Q1'26: +1,092.0% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-16.4% Q1'26: -16.2% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+0.2% Q1'26: +2.5% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%+0.1% Q1'26: +1.3% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+6.8% Q1'26: +4.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×13.91× Q1'26: 11.25× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.00% | 548.2K | 0.06% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 166.8K | 0.29% |
| 3 | Vanguard FTSE Pacific ETF VPL | 0.00% | 237.1K | 0.07% |
| 4 | Vanguard FTSE Developed Asia Pacific All Cap Index ETF VA.TO | 0.00% | 3.3K | 0.22% |
| 5 | Vanguard FTSE Developed All Cap ex North America Index ETF VIU.TO | 0.00% | 52.5K | 0.23% |
| 6 | Vanguard FTSE Developed All Cap ex North America Index ETF (CAD-hedged) VI.TO | 0.00% | 4.5K | 0.22% |
| 7 | Vanguard FTSE Developed All Cap ex U.S. Index ETF VDU.TO | 0.00% | 3.8K | 0.22% |
| 8 | Vanguard FTSE Developed All Cap ex U.S. Index ETF (CAD-hedged) VEF.TO | 0.00% | 5.8K | 0.22% |
| 9 | Vanguard FTSE Developed Markets ETF VEA | 0.00% | 1.98M | 0.03% |
| 10 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 54.2K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 041960.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
